Office Action Predictor
Last updated: April 16, 2026
Application No. 17/918,230

METHODS AND COMPOSITIONS FOR INACTIVATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE (ITK)

Final Rejection §101§112
Filed
Oct 11, 2022
Examiner
GIBBS, TERRA C
Art Unit
1635
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Research Foundation For The State University Of New York
OA Round
2 (Final)
64%
Grant Probability
Moderate
3-4
OA Rounds
2y 8m
To Grant
69%
With Interview

Examiner Intelligence

Grants 64% of resolved cases
64%
Career Allow Rate
606 granted / 946 resolved
+4.1% vs TC avg
Moderate +5% lift
Without
With
+5.2%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
41 currently pending
Career history
987
Total Applications
across all art units

Statute-Specific Performance

§101
5.7%
-34.3% vs TC avg
§103
32.8%
-7.2% vs TC avg
§102
18.5%
-21.5% vs TC avg
§112
26.7%
-13.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 946 resolved cases

Office Action

§101 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION This Office Action is a response to Applicant’s Amendment and Remarks filed January 16, 2026. Claims 26, 28 and 29 have been amended. Claims 1-29 are pending in the present application. This application contains claims 1-25 drawn to an invention nonelected without traverse in the reply filed August 25, 2025. A complete reply to the final rejection must include cancellation of nonelected claims or other appropriate action (37 CFR 1.144). See MPEP § 821.01. Accordingly, claims 26-29 have been examined on the merits as detailed below: The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Information Disclosure Statement It is noted that Applicants have not filed an information disclosure statement under § 1.97(c). Applicant is reminded of 37 CFR § 1.56, which details Applicants duty to disclose all information known to be material to patentability. Nucleotide Sequence Disclosures In the previous Office Action mailed September 17, 2025, it was noted that this application failed to comply with the requirements of 37 C.F.R. §1.821-1.825. In view of Applicant’s Amendment to the Specification filed January 16, 2026, it is noted that the application is fully compliant with the sequence requirements of 37 C.F.R. §1.821-1.825. Claim Rejections - 35 USC § 112 In the previous Office Action mailed September 17, 2025, claim 28 was rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. This rejection is withdrawn in view of Applicant’s Amendment to the claim filed January 16, 2026. ****** In the previous Office Action mailed September 17, 2025, claims 26-29 were rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. This rejection is withdrawn in view of Applicant’s Amendment to the claims filed January 16, 2026. Claim Rejections - 35 USC § 101 In the previous Office Action mailed September 17, 2025, claims 28 and 29 were rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. This rejection is withdrawn in view of Applicant’s Amendment to the claims filed January 16, 2026. Applicant's amendment to the claims filed January 16, 2026 necessitated the new ground(s) of rejection presented below: Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 26-29 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for pre-AIA the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a new matter rejection. Claim 26 has been amended and the Invention is now drawn to a synthetic nucleic acid encoding a peptide inhibitor having sequence identity to SEQ ID NO: 2, wherein the peptide inhibitor comprises a phosphorylated tyrosine, and wherein the peptide inhibitor is a polypeptide comprising fewer than 50 amino acids. In Applicant’s Response filed January 16, 2026, Applicants indicate that support for the amendment to claim 26 can be found in paragraph [0057]. Applicants also submit that this paragraph “clearly supports the inclusion of polypeptides with fewer than 50 amino acids”. Paragraph [0057] discloses: The terms “peptide,” “polypeptide,” and “protein” are used interchangeably herein, and refer to a polymeric form of amino acids of any length, which can include coded and non-coded amino acids, chemically or biochemically modified or derivatized amino acids, and polypeptides having modified peptide backbones. A review of paragraph [0074] does not support the specific limitation, “wherein the peptide inhibitor is a polypeptide comprising fewer than 50 amino acids”. Therefore, this limitation is new matter. If Applicants believe the Specification supports “wherein the peptide inhibitor is a polypeptide comprising fewer than 50 amino acids”, the Examiner urges Applicant to point to, with particularity, where support can be found for the claims as now filed. Otherwise, Applicant is required to cancel the new matter in reply to this Office Action. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Terra C. Gibbs whose telephone number is 571-272-0758. The Examiner can normally be reached from 8 am - 5 pm M-F. If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Ram Shukla can be reached on 571-272-0735. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public. For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199. /TERRA C GIBBS/Primary Examiner, Art Unit 1635
Read full office action

Prosecution Timeline

Oct 11, 2022
Application Filed
Sep 15, 2025
Non-Final Rejection — §101, §112
Jan 16, 2026
Response Filed
Jan 30, 2026
Final Rejection — §101, §112
Apr 03, 2026
Response after Non-Final Action

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600998
Large Scale Synthesis of Messenger RNA
2y 5m to grant Granted Apr 14, 2026
Patent 12590129
LIVER-SPECIFIC REGULATORY NUCLEIC ACID SEQUENCES
2y 5m to grant Granted Mar 31, 2026
Patent 12590305
COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
2y 5m to grant Granted Mar 31, 2026
Patent 12584128
COMPOSITIONS FOR MODULATING ATAXIN 2 EXPRESSION
2y 5m to grant Granted Mar 24, 2026
Patent 12569561
DOUBLE STRANDED OLIGONUCLEOTIDE CONSTRUCT COMPRISING ANDROGEN RECEPTOR SPECIFIC SEQUENCE, AND COMPOSITION FOR PREVENTING HAIR LOSS AND PROMOTING HAIR GROWTH COMPRISING SAME
2y 5m to grant Granted Mar 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
64%
Grant Probability
69%
With Interview (+5.2%)
2y 8m
Median Time to Grant
Moderate
PTA Risk
Based on 946 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in for Full Analysis

Enter your email to receive a magic link. No password needed.

Free tier: 3 strategy analyses per month